LQDA
NASDAQLiquidia Corporation
Price$34.33+0.38 (+1.13%)
01:30 PM07:45 PM
News · 26 weeks109+122%
2026-04-192026-10-11
Mix4390d
- Insider19(44%)
- Other9(21%)
- SEC Filings9(21%)
- Analyst4(9%)
- Earnings1(2%)
- Market1(2%)
Latest news
25 items- ANALYSTLiquidia Technologies upgraded by BTIG Research with a new price targetBTIG Research upgraded Liquidia Technologies from Neutral to Buy and set a new price target of $70.00
- SECSEC Form 8-K filed by Liquidia Corporation8-K - Liquidia Corp (0001819576) (Filer)
- INSIDERSEC Form 4 filed by Liquidia Corporation4 - Liquidia Corp (0001819576) (Issuer)
- INSIDERSEC Form 4 filed by Liquidia Corporation4 - Liquidia Corp (0001819576) (Issuer)
- INSIDERSEC Form 4 filed by Liquidia Corporation4 - Liquidia Corp (0001819576) (Issuer)
- INSIDERSEC Form 4 filed by Liquidia Corporation4 - Liquidia Corp (0001819576) (Issuer)
- INSIDERSEC Form 4 filed by Liquidia Corporation4 - Liquidia Corp (0001819576) (Issuer)
- INSIDERSEC Form 4 filed by Liquidia Corporation4 - Liquidia Corp (0001819576) (Issuer)
- INSIDERSEC Form 4 filed by Liquidia Corporation4 - Liquidia Corp (0001819576) (Issuer)
- INSIDERSEC Form 4 filed by Liquidia Corporation4 - Liquidia Corp (0001819576) (Issuer)
- INSIDERSEC Form 4 filed by Liquidia Corporation4 - Liquidia Corp (0001819576) (Issuer)
- PRLIQUIDIA CORPORATION LQDA INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 57.2% Share DropThe law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ:LQDA) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM’S INVESTIGATION]What Happened?On September 30, 2026, the U.S. District Court for the District of Delaware found that Liquidia’s lead commercial product used to treat pulmonary hypertension, Yutrepia inhalation powder, infringed two of six claims of United Therapeutics Corporation’s ‘327 patent. The Court ruled that Yutrepia infringed claims 1 and 14 of t
- PRLiquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAHFully resolves all six ongoing lawsuits between the companiesMaintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial hypertension (PAH)Liquidia to pay net $380.7 million in multiple installments in 2026 and 2027, inclusive of payments to resolve antitrust litigation against United TherapeuticsStrong financial position with $222.7 million in Q3’26 YUTREPIA net product sales (preliminary, unaudited), contributing to $396.1 million in cash and cash equivalents as of September 30, 2026Liquidia will continue to advance YUTREPIA and L606 clinical programs as previously outlined MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a
- INSIDERSEC Form 4 filed by Liquidia Corporation4 - Liquidia Corp (0001819576) (Issuer)
- NEWSLQDA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Liquidia Corporation (LQDA)NEW YORK CITY, NY / ACCESS Newswire / October 7, 2026 / Liquidia Corporation (NASDAQ:LQDA) shares fell roughly 57% after a court ruled that Yutrepia infringes two valid claims of United Therapeutics' '327 patent. If you held LQDA when the ruling hit and lost money, you may have legal rights. Shareholders who suffered losses are encouraged to submit their loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.Levi & Korsinsky is investigating potential securities law violations, including whether Liquidia may not have adequately disclosed the risks tied to the '327 patent case. Trial was held in June 2025. The cou
- ANALYSTLiquidia Technologies downgraded by Wells Fargo with a new price targetWells Fargo downgraded Liquidia Technologies from Overweight to Equal Weight and set a new price target of $30.00
- ANALYSTLiquidia Technologies downgraded by Raymond James with a new price targetRaymond James downgraded Liquidia Technologies from Strong Buy to Outperform and set a new price target of $53.00
- ANALYSTLiquidia Technologies downgraded by BTIG ResearchBTIG Research downgraded Liquidia Technologies from Buy to Neutral
- SECLiquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Liquidia Corp (0001819576) (Filer)
- PRLiquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 PatentDistrict Court ruled that two of the six claims asserted against Liquidia are valid and infringedParties directed to submit form of judgment, specifying the proposed remedy, for the District Court’s consideration within one week MORRISVILLE, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today issued an update regarding the litigation filed by United Therapeutics Corporation (UTHR) in the U.S. District Court for the District of Delaware (the Court) under the Hatch-Waxman Act concerning U.S. Patent No. 11,826,327 (
- INSIDERDirector Singh Raman exercised 17,492 shares at a strike of $9.28 and sold $1,179,453 worth of shares (17,492 units at $67.43) (SEC Form 4)4 - Liquidia Corp (0001819576) (Issuer)
- SECSEC Form 144 filed by Liquidia Corporation144 - Liquidia Corp (0001819576) (Subject)
- SECSEC Form 144 filed by Liquidia Corporation144 - Liquidia Corp (0001819576) (Subject)
- INSIDERChief Human Resource Officer Krepp Sarah sold $18,566 worth of shares (274 units at $67.76) as part of a pre-agreed trading plan, decreasing direct ownership by 0.23% to 117,308 units (SEC Form 4)4 - Liquidia Corp (0001819576) (Issuer)
- SECLiquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Liquidia Corp (0001819576) (Filer)
LQDA FAQ
7 questionsWhat does Liquidia Corporation do?
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Where does LQDA stock trade?
Liquidia Corporation (LQDA) is listed on NASDAQ.What sector and industry is LQDA in?
Liquidia Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Liquidia Corporation go public?
Liquidia Corporation (LQDA) completed its IPO in 2018.What are analysts saying about LQDA?
Liquidia Corporation has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy on 2026-10-14. Recent price targets range from $1300.00 to $4300.00.What companies are similar to LQDA?
Notable peers in the same industry include UTHR (United Therapeutics Corporation), TVTX (Travere Therapeutics Inc.), VCYT (Veracyte Inc.). Compare LQDA side-by-side with any of them on Quantisnow.How can I track LQDA on Quantisnow?
Quantisnow aggregates Liquidia Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LQDA to receive live email and push alerts on every new disclosure.